WCM
IDXX icon

Westend Capital Management’s Idexx Laboratories IDXX Stock Holding History

Westend Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$7.3K – 273
2026
Q1 		$7.3K Hold
13
– – ﹤0.01% 176
2025
Q4 		$8.79K Hold
13
– – ﹤0.01% 161
2025
Q3 		$8.31K Hold
13
– – ﹤0.01% 151
2025
Q2 		$6.97K Hold
13
– – ﹤0.01% 145
2025
Q1 		$5.46K Hold
13
– – ﹤0.01% 149
2024
Q4 		$5.38K Hold
13
– – ﹤0.01% 157
2024
Q3 		$6.57K Hold
13
– – ﹤0.01% 149
2024
Q2 		$6.19K Hold
13
– – ﹤0.01% 128
2024
Q1 		$7.02K Buy
+13
New +$7.1K ﹤0.01% 140

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Westend Capital Management's IDXX Position: Q2 2026 in Review

Westend Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 13 shares — an estimated $7.3K sold.

Westend Capital Management first reported a position in IDXX in Q1 2024 and held it in 9 quarters. The position peaked at $8.79K in Q4 2025. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Westend Capital Management reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Westend Capital Management sold 13 Idexx Laboratories shares in Q2 2026, an estimated $7.3K.
  • Westend Capital Management first reported a position in Idexx Laboratories in Q1 2024 and held it in 9 quarters.
  • Westend Capital Management's Idexx Laboratories position peaked at $8.79K in Q4 2025.
  • 1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Westend Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.